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136 The Journal of Thoracic and CardioBackground: Management of solitary adrenal metastasis from non–small cell lung
cancer is still debated. Although classically considered incurable, various reports
with small numbers of patients have shown that surgical treatment might improve
long-term survival. The aim of this study was to review our experience and to
identify factors that could affect survival.
Methods: From January 1989 through April 2003, 23 patients underwent complete
resection of an isolated adrenal metastasis after surgical treatment of non–small cell
lung cancer. There were 19 men and 4 women, with a mean age of 54  10 years.
The diagnosis of adrenal metastasis was synchronous with the diagnosis of non–
small cell lung cancer in 6 patients and metachronous in 17 patients. The median
disease-free interval for patients with metachronous metastasis was 12.5 months
(range, 4.5-60.1 months).
Results: The overall 5-year survival was 23.3%. Univariate and multivariate anal-
ysis demonstrated that a disease-free interval of greater than 6 months was an
independent and significant predictor of increased survival in patients after adre-
nalectomy. All patients with a disease-free interval of less than 6 months died within
2 years of the operation. The 5-year survival was 38% after resection of an isolated
adrenal metastasis that occurred more than 6 months after lung resection. Adjuvant
therapy and pathologic staging of non–small cell lung cancer did not affect survival.
Conclusions: Surgical resection of metachronous isolated adrenal metastasis with a
disease-free interval of greater than 6 months can provide long-term survival in
patients previously undergoing complete resection of the primary non–small cell
lung cancer.
Adrenal glands are a common metastatic site for non–small cell lung cancer(NSCLC). Metastases are the sign of a general spread of disease and usuallyoccur as multiple metastases. Solitary adrenal metastasis from NSCLC is a
rare event. The incidence was evaluated in 2 prospective studies to be only 1.6%1
and 3.5%2 of resectable NSCLC. Nonsurgical treatment of a solitary adrenal
metastasis is associated with poor survival. Over the last 10 years, several obser-
vations and short case series have observed that long-term survival after adrenal-
ectomy was possible.2-7 Multicenter reports suggested that surgical treatment of
solitary adrenal metastasis from resectable NSCLC could potentially improve sur-
vival.8 We report our experience with surgical treatment of solitary adrenal metas-
tasis from resectable NSCLC. The aim of this study was to evaluate the result of
surgical treatment on survival and to establish the variables that could influence
survival to select patients who could expect a benefit from adrenalectomy.
Patients and Methods
Between January 1989 and April 2003, 33 of 3125 patients undergoing lung cancer
resections in our department were found to have an isolated adrenal mass. After an
vascular Surgery ● July 2005
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nal masses that were compatible with an isolated adrenal me-
tastasis were completely resected. A total of 23 patients were
given a diagnosis of an isolated adrenal metastasis from
NSCLC, and these patients form the basis of the present study.
Ten patients presented with an adenoma of the adrenal gland
that was unrelated to the diagnosis of NSCLC.
There were 19 men and 4 women, with a mean age of 54 
10 years (range, 35-70 years). All patients underwent spiral
computed tomography (CT) scanning of the thorax and upper
abdomen, as well as cerebral CT scanning, as part of the staging
for NSCLC. Bone scanning was performed in symptomatic
patients or in patients with abnormal alkaline phosphatase lev-
els. Mediastinoscopy was performed when thoracic CT scan-
ning detected mediastinal lymph nodes with a short-axis diam-
eter of 1 cm or more. Patients with involvement of mediastinal
lymph nodes proved histologically underwent induction chemo-
therapy before the operation. In all patients complete resection
of the primary lung cancer was performed before the adrenal-
ectomy (Table 1). Mediastinal lymphadenectomy or lymph
node sampling was performed in all patients.
Diagnosis of Isolated Adrenal Metastasis
All patients were asymptomatic at the time of presentation. Six
patients presented with an isolated adrenal metastasis discovered
TABLE 1. Characteristics of patients who underwent lung a
metastases
Patient no.
Primary lung
cancer
classification
Primary lung
cancer
histologic type DFI (mo)
1 T2 N1 M0 LCC 5
2 T2 N1 M0 SCC 10
3 T2 N1 M0 ADK 7
4 T3 N0 M0 SCC 13
5 T2 N2 M0 ADK 24
6 T2 N1 M0 SCC 8
7 T3 N1 M0 ADK 9
8 T2 N1 M0 SCC/ADK 6
9 T2 N1 M0 SCC 24
10 T3 N1 M1 ADK 0
11 T4 N2 M0 SCC 6
12 T2 N0 M1 SCC 0
13 T2 N0 M0 SCC 20
14 T3 N0 M0 LCC 14
15 T2 N1 M1 ADK 0
16 T2 N1 M0 SCC 18
17 T1 N0 M0 ADK 15
18 T3 N2 M0 SCC 6
19 T2 N1 M1 ADK 0
20 T2 N2 M0 ADK 14
21 T3 N0 M0 ADK 60
22 T3 N0 M1 ADK 0
23 T4 N1 M1 SCC 0
DFI, Disease-free interval; LCC, large cell carcinoma; SCC, squamous cellduring the preoperative workup of the primary lung tumor (syn-
The Journal of Thoracichronous metastasis). The remaining 17 patients presented with a
metastasis that was discovered during follow-up after the primary
lung tumor was resected surgically (metachronous metastasis). In
10 patients the metastasis was detected on routine follow-up chest
CT scanning, and in 7 patients an increased serum carcinoembry-
onic antigen (CEA) level prompted a metastatic search by means
of CT scanning.
We defined a disease-free interval (DFI) corresponding to
the time interval between the surgical treatment of the primary
tumor and the diagnosis of the adrenal metastasis. For synchro-
nous metastasis, this interval was nil. Survival was calculated
from the date of adrenalectomy to death or the date of last
follow-up. Disease-free survival is defined as the time interval
from the adrenalectomy to the date of last follow-up or the date
of disease recurrence. Complete follow-up was available for all
patients.
Treatment of Isolated Adrenal Metastasis
Complete unilateral adrenalectomy was performed by means of
either a transperitoneal approach (n  14) or an extraperitoneal
approach (n  9), depending on the tumor’s size. Small tumors
without local invasion were removed through a right or left upper
quadrant laparotomy. Adjacent organs, such as the kidney (n 2),
inferior vena cava (n  1), or the liver (n  1), were partially
resected en bloc with the tumor in 4 patients. Routine frozen
drenal gland resection for synchronous and metachronous
Adjuvant therapy
after
adrenalectomy Status Recurrences
Survival after
adrenalectomy
(mo)
None Dead Yes 7
None Dead Yes 41
None Dead No 100
None Dead Yes 16
Chemo Alive No 110
Rx Alive Yes 94
Rx Dead Yes 6
None Dead Yes 11
None Dead Yes 2
Rx/Chemo Dead Yes 16
None Dead Yes 5
None Dead Yes 2
Rx/Chemo Dead No 9
None Alive No 30
Rx Dead No 8
None Dead Yes 34
Rx/Chemo Alive Yes 41
Rx/Chemo Dead Yes 16
None Dead No 10
Rx/Chemo Dead Yes 13
Rx/Chemo Alive No 14
Chemo Alive No 9
None Alive No 0.3
inoma; ADK, adenocarcinoma; Chemo, chemotherapy; Rx, radiotherapy.nd asections were obtained to ensure excision of the tumor with tumor-
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formed. Decisions for complementary treatment, such as localized
radiation therapy or chemotherapy, were made on a case-by-case
basis after discussion with the medical oncologist. No particular
criteria were defined for adjuvant treatment.
Statistical Analysis
All results are expressed as means SE. Survivals were calculated
by means of life-table analysis. Kaplan-Meier curves were plotted
and compared by using the log-rank test for univariate analysis.
Variables tested were sex, serum CEA level, DFI, metachronous or
synchronous metastasis, T and N status of the primary lung cancer,
histology of the primary lung cancer, adjuvant chemotherapy,
adjuvant radiotherapy of the adrenal bed, metastasis location (ho-
molateral or contralateral), size of adrenal metastasis, and invasion
of the adrenal capsule. Multivariate analysis of independent prog-
nostic factors was assessed by using the Cox proportional hazards
stepwise model with Statview V (Abacus Concept, Berkeley,
Calif).
Results
Primary Lung Cancer
Histologic findings and stages of the primary lung cancer
are presented in Table 1. Neoadjuvant platinum-based che-
motherapy was administered to 2 patients who had histo-
logically proved N2 disease and 1 patient with synchronous
adrenal metastasis. All other patients have been initially
treated with complete surgical resection of the primary
tumor. Adjuvant platinum-based chemotherapy and radia-
tion therapy of the mediastinum (mean, 50 Gy) was given to
patients with postoperatively proved N2 disease (n  4) or
with locally advanced tumor (T3 or T4, n  7). Three
patients with synchronous adrenal metastasis also received
adjuvant platinum-based chemotherapy and radiation ther-
Figure 1. Overall survival of the 23 patients after resection of
solitary adrenal metastasis from resected NSCLC calculated with
the Kaplan-Meier method.apy of the adrenal bed.
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The median size of the adrenal metastasis was 5.8 cm
(range, 2-11 cm). The median DFI for patients with meta-
chronous metastasis was 12.5 months (range, 4.5-60.1
months). Synchronous metastases of the adrenal gland were
resected a mean of 2 months (range, 0.5-4 months) after
lung resection in 5 patients and during the same operative
procedure in 1 patient. There were no perioperative deaths.
However, 3 (13%) patients experienced postoperative com-
plications: one bronchopleural fistula successfully treated
with thoracoplasty and antibiotics, one covered evisceration
on the ninth postoperative day treated surgically, and one
cardiac arrhythmia treated medically.
Histologic findings confirmed the diagnosis of NSCLC
metastasis. Surgical margins were free of disease in all
patients. However, tumor invaded the adrenal capsule in 15
(65%) patients. Twelve (52%) patients underwent adjuvant
therapy: 3 cycles of platinum-based chemotherapy alone
(n  3), radiation therapy (mean, 45 Gy) to the adrenal bed
alone (n  3), and a combination of radiation and chemo-
therapy (n  6).
The mean follow-up period after adrenalectomy was 26
months (range, 0.3-110 months). During follow-up, 14
(61%) patients had recurrence of NSCLC. Recurrence was
local (in the operated adrenal bed) in 4 patients, local and
systemic in 1 patient, and systemic in 9 patients. Systemic
recurrence was limited to only one distant organ in 5 pa-
tients, the brain (n 3), the contralateral adrenal gland (n
1), and the contralateral lung (n  1), and was spread to
multiple organs in the other 5 patients.
All patients presenting with local recurrences had cap-
sular invasion of the adrenal gland on histologic examina-
tion. Local recurrence was not significantly different be-
tween patients undergoing adjuvant therapy or not. Local
recurrences were treated with radiation therapy (mean, 60
Figure 2. Kaplan-Meier disease-free survival curve of the 23
patients after resection of solitary adrenal metastasis from re-
sected NSCLC.Gy) in 3 patients and with an extended surgical resection
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tient is currently alive and free of disease 88 months later.
After a median survival of 13.3 months, the 2- and 5-year
survivals were 37% and 23.3%, respectively (Figure 1). The
overall median disease-free survival was 8 months, and the
5-year disease free survival was 18% (Figure 2). TNM
status, histology of the lung cancer, adjuvant therapy, pre-
operative serum CEA level, metastasis location (homolat-
eral or contralateral) and size, and capsular invasion of the
adrenal gland did not influence survival. Univariate and
multivariate analysis demonstrated that a DFI of greater
than 6 months was the only significant and independent
predictor of increased survival in patients after adrenalec-
tomy (Table 2). All patients with a DFI of less than 6
months died within 2 years after resection of the adrenal
gland, whereas 38% of the patients with a DFI of greater
than 6 months were alive at 5 years after adrenalectomy
(Figure 3).
Discussion
Although management of isolated adrenal metastases from
NSCLC is still debated, this study demonstrates that surgical
resection can provide long-term survival without operative
death or major complications. The 5-year survival reached
38% after resection of an isolated metachronous adrenal me-
tastasis occurring more than 6 months after resection of the
primary lung cancer, whereas all patients with synchronous
metastasis or with a DFI of less than 6 months died within 2
years after the adrenalectomy. A DFI of greater than 6 months
was the only independent predictor of increased survival.
Other factors, such as the T and N staging of the primary
tumor, histology, administration of adjuvant therapy, or size of
the metastasis, had no effect on survival.
During the last 2 decades, several case reports and small
series showed long-term survival after surgical resection of
isolated adrenal metastasis if complete resection of both the
TABLE 2. Predictor factors of worse survival
Predictor factors
Univariate
analysis P
value
Multivariate
analysis P
value
T .74 –
N .71 –
Adrenal capsule invasion .71 –
Size of adrenal metastasis .41 –
Adenocarcinoma or not .43 –
Adjuvant therapy .28 –
Serum CEA level .27 –
Homolateral-contralateral .89 –
Synchronous-metachronous .1 –
DFI 6 mo .005 .01
CEA, Carcinoembryonic antigen; DFI, disease-free interval.primary tumor and the metastasis could be achieved (Table
The Journal of Thoraci3).6,8-12 Hence our policy over the past 15 years in patients
with resectable NSCLC has been to remove all adrenal masses
that were compatible with an isolated adrenal metastasis after
an extensive workup was performed. Fluorodeoxyglucose
positron emission tomography was used to rule out metastasis
to other locations than the adrenal gland during the last 4 years
of the study. Interestingly, despite positive fixation on preop-
erative positron emission tomography scanning in 4 patients,
one was found to have a benign adenoma on postoperative
histology.
In agreement with previous studies,2,4-10,13-16 our results
confirmed that resection of adrenal metastasis can improve
survival in patients with complete resection of their NSCLC.
We observed 3 patients alive more than 5 years after the
adrenalectomy and found a 5-year survival of 23.3% (Figure
1). These results are similar to the survivals of patients under-
going isolated brain metastasis resection.17-20 Surgical treat-
ment of solitary brain metastasis from NSCLC has been shown
to improve survival compared with radiotherapy17 and to be
associated with 5-year survivals ranging between 13% and
30%.18-20
We could also corroborate our results to those from Higash-
iyama and colleagues11 and Kim and associates,21 who found
that a DFI of less than 6 months and synchronous metastasis
were associated with worse survivals. This finding suggests
that a DFI of less than 6 months is an indicator of either tumor
aggressiveness or advanced tumor stage that remained unde-
tected at the time of resection of the primary tumor. We
observed that no patients with synchronous metastasis or with
a DFI of less than 6 months survived more than 2 years after
the operation in our series. Induction therapy could potentially
improve survival in this group of patients. Luketich and Burt14
reported a much better median survival (31 months) than we
did in patients with synchronous metastases after neoadjuvant
chemotherapy and adrenal resection. Further studies are re-
quired to confirm this finding.
Conclusion
In conclusion, long-term survival after resection of isolated
Figure 3. Kaplan-Meier survival curves according to DFI.NSCLC metastasis to the adrenal gland is possible. A DFI of
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ences survival. Hence, surgical resection of metachronous iso-
lated adrenal metastasis should be the treatment of choice if the
DFI is greater than 6 months and complete resection of the
primary NSCLC is achieved.
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